Apolipoprotein C3
Apolipoprotein C3 (APOC3) is a protein that in humans is encoded by the APOC3 gene located on chromosome 11. APOC3 is a component of very low-density lipoprotein (VLDL) and is involved in lipid metabolism, playing a significant role in the regulation of triglyceride levels in the blood. Elevated levels of APOC3 have been associated with hypertriglyceridemia, a risk factor for atherosclerosis and cardiovascular disease.
Function[edit | edit source]
APOC3 inhibits the activity of lipoprotein lipase (LPL) and hepatic lipase (HL), enzymes that are crucial for the hydrolysis of triglycerides. By inhibiting these enzymes, APOC3 reduces the clearance of triglyceride-rich lipoproteins from the blood, leading to increased levels of plasma triglycerides. APOC3 also affects the hepatic uptake of triglyceride-rich particles, further influencing lipid levels in the bloodstream.
Genetic Regulation[edit | edit source]
The APOC3 gene is regulated by several factors, including insulin, which suppresses its expression. Variants in the APOC3 gene have been linked to differences in plasma triglyceride levels among individuals. Certain mutations can lead to either the overproduction or deficiency of APOC3, each having distinct effects on lipid metabolism and disease risk.
Clinical Significance[edit | edit source]
High levels of APOC3 are associated with the development of hypertriglyceridemia, which is a known risk factor for atherosclerosis and cardiovascular disease. Conversely, individuals with mutations leading to APOC3 deficiency tend to have lower triglyceride levels and a reduced risk of cardiovascular disease, suggesting that APOC3 could be a potential target for therapeutic intervention.
Research has also explored the role of APOC3 in other conditions, such as non-alcoholic fatty liver disease (NAFLD) and insulin resistance, indicating its broad impact on metabolic health.
Therapeutic Implications[edit | edit source]
Given its role in lipid metabolism, APOC3 has become a target for the development of drugs aimed at reducing triglyceride levels. Inhibitors of APOC3 are being investigated for their potential to lower the risk of cardiovascular disease in individuals with hypertriglyceridemia.
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD